Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇺🇸
Community Health Network, Inc., Indianapolis, Indiana, United States
🇺🇸Cayuga Cancer Center at Cayuga Park, Ithaca, New York, United States
🇺🇸Cayuga Medical Center, Ithaca, New York, United States
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT06055075
- Locations
- 🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of
🇦🇺Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Dong-A University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT05909826
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Carl Ola Landgren, MD, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT05896228
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 83
- Registration Number
- NCT05789303
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05675449
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
🇺🇸Johns Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
Home Treatment With Carfilzomib in Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Thomas Lund
- Target Recruit Count
- 12
- Registration Number
- NCT05620238
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.